Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
This study has been completed.
Study NCT01341639   Information provided by Sanofi Pasteur MSD

First Received on April 22, 2011.   Last Updated on April 9, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bacterial Infections
Virus Diseases
Interventions listed in this trial
V419
INFANRIX hexa
RotaTeq
Prevenar 13
ProQuad
Sponsors listed in this trial
Sanofi Pasteur MSD
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services